Taysha Gene Therapies (NASDAQ:TSHA) Receives Buy Rating from Chardan Capital

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reaffirmed by Chardan Capital in a report issued on Thursday,Benzinga reports. They currently have a $12.00 target price on the stock. Chardan Capital’s price target points to a potential upside of 163.45% from the stock’s current price.

Other equities analysts have also recently issued reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, March 3rd. The Goldman Sachs Group set a $11.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. Wells Fargo & Company lifted their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, December 29th. Finally, Wall Street Zen downgraded shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.91.

Taysha Gene Therapies Stock Performance

TSHA traded up $0.11 during trading on Thursday, hitting $4.56. 3,706,851 shares of the stock were exchanged, compared to its average volume of 2,599,940. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $6.02. The stock has a fifty day moving average price of $4.66 and a two-hundred day moving average price of $4.53. The firm has a market capitalization of $1.25 billion, a P/E ratio of -13.80 and a beta of 1.02.

Insider Buying and Selling

In other Taysha Gene Therapies news, CFO Kamran Alam sold 23,849 shares of the company’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $109,943.89. Following the completion of the transaction, the chief financial officer owned 1,443,786 shares in the company, valued at approximately $6,655,853.46. This represents a 1.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sean P. Nolan sold 41,312 shares of the firm’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $4.61, for a total transaction of $190,448.32. Following the completion of the sale, the chief executive officer owned 2,908,257 shares of the company’s stock, valued at $13,407,064.77. This trade represents a 1.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 598,623 shares of company stock valued at $2,822,188 over the last three months. 3.78% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Marex Group plc purchased a new position in Taysha Gene Therapies during the second quarter worth about $29,000. E Fund Management Co. Ltd. purchased a new stake in Taysha Gene Therapies in the 2nd quarter valued at approximately $31,000. ST Germain D J Co. Inc. boosted its holdings in Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after purchasing an additional 4,333 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Taysha Gene Therapies during the 3rd quarter worth approximately $40,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after buying an additional 10,742 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.